Table 1.
Baseline characteristics of patients recruited to the discovery phase.
| Discovery Phase | ||
|---|---|---|
| Control Cohort (n = 20) |
Patients on 81 mg ASA (n = 40) |
|
| Mean (SD) | ||
| Age (yrs) | 58 (19) | 68 (9) |
| Platelet Count (108/mL) | 186 (62) | 209 (70.47) |
| WBC (108/mL) | 6.2 (2.0) | 6.8 (1.7) |
| HCT | 0.380 (0.04) | 0.384 (0.03) |
| Frequency (%) | ||
| Sex (male) | 15 (75) | 28 (70) * |
| Hypertension | 8 (40) | 28 (70) * |
| Hyperlipidemia | 8 (40) | 32 (80) * |
| Diabetes | 2 (10) | 15 (37) * |
| Smoking | 7 (35) | 30 (75) * |
| CAD | 0 (0) | 12 (30) * |
| PAD | 5 (13) | 24 (60) * |
| Medication (%) | ||
| Statin | 9 (45) | 33 (83) * |
| ACEi/ARB | 6 (30) | 21 (53) * |
| B-blockers | 1 (5) | 9 (23) * |
Acetylsalicylic acid, ASA; white blood cells, WBC; hematocrit, HCT; angiotensin-converting enzyme inhibitors ACEi/Arb; coronary artery disease, CAD; peripheral arterial disease, PAD. Continuous variables are shown as mean (standard deviation). Categorical variables are shown as frequency (%). * represents significant difference (p < 0.05) between controls not taking ASA and patients on 81 mg of ASA.